ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.727,68
0,36%
Brent Oil
81,295
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) Notícias

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BPMC
DataHoraFonteTítuloCódigoCompanhia
31/05/202417:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
30/05/202419:01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
24/05/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202418:05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
17/05/202417:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202417:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202408:00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202409:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202409:00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
23/02/202410:00PR Newswire (US)Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
16/02/202418:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BPMCBlueprint Medicines Corporation
15/02/202419:26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPMCBlueprint Medicines Corporation
15/02/202409:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
01/02/202410:00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024NASDAQ:BPMCBlueprint Medicines Corporation
08/01/202410:00PR Newswire (US)Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202310:00PR Newswire (US)Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
12/12/202310:05PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
09/12/202314:30PR Newswire (US)Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
28/11/202310:00PR Newswire (US)Blueprint Medicines to Present at JMP Securities Hematology and Oncology SummitNASDAQ:BPMCBlueprint Medicines Corporation
10/11/202310:00PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
26/10/202317:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPMCBlueprint Medicines Corporation
26/10/202308:00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
23/10/202309:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:BPMCBlueprint Medicines Corporation
12/10/202309:00PR Newswire (US)Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023NASDAQ:BPMCBlueprint Medicines Corporation
02/08/202308:00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
19/07/202309:00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023NASDAQ:BPMCBlueprint Medicines Corporation
30/06/202307:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
23/06/202320:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
03/06/202310:00PR Newswire (US)Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202311:00PR Newswire (US)NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:BPMC

Seu Histórico Recente

LSE
UC41
Citi Fun 25
BOV
BBSEE310
BBSEE310 Ex:28,14
NASDAQ
FLTCBX
Richard Bernstein Adviso...
NYSE
USB-M
US Bancorp
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados